Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Conjugated Proteins02:50

Conjugated Proteins

18.3K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.3K
Leaky Scanning02:28

Leaky Scanning

5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.

Nature medicine·2026
Same author

LP.8.1-directed COVID-19 mRNA vaccines durably boost neutralizing antibodies and mitigate ancestral immune imprinting.

PLoS pathogens·2026
Same author

Serum neutralisation of H5N1 clade 2.3.4.4b influenza is largely mediated by neuraminidase-directed antibodies.

The Lancet. Microbe·2026
Same author

Comparative Proteomic Analysis of Lipoprotein(a): Method-Dependent Profiles and Disease Pathways.

Journal of clinical medicine·2026
Same author

LP.8.1-directed COVID-19 mRNA vaccines durably boost neutralizing antibodies and mitigate ancestral immune imprinting.

bioRxiv : the preprint server for biology·2026
Same author

Alzheimer's disease risk protein SorLA regulates ER homeostasis and lipid metabolism in human microglia, with conserved effects in neurons.

Acta neuropathologica·2026

Related Experiment Video

Updated: Jul 1, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.3K

Developing inhibitory peptides against SARS-CoV-2 envelope protein.

Ramsey Bekdash1,2,3, Kazushige Yoshida1,2, Manoj S Nair4

  • 1Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, New York, United States of America.

Plos Biology
|March 14, 2024
PubMed
Summary

Researchers developed novel peptides, iPep-SARS2-E, targeting the conserved SARS-CoV-2 Envelope protein. These peptides effectively inhibit viral propagation and cytotoxicity in vitro and in vivo, offering a potential therapeutic strategy for coronaviruses.

More Related Videos

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
07:53

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation

Published on: January 9, 2019

33.2K
Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques
08:07

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques

Published on: January 12, 2024

717

Related Experiment Videos

Last Updated: Jul 1, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.3K
A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
07:53

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation

Published on: January 9, 2019

33.2K
Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques
08:07

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques

Published on: January 12, 2024

717

Area of Science:

  • Virology
  • Drug Discovery
  • Molecular Biology

Background:

  • The COVID-19 pandemic, caused by SARS-CoV-2, poses a significant global health challenge.
  • High mutation rates in SARS-CoV-2 complicate prevention and treatment strategies.
  • The conserved Envelope (E) protein across human coronaviruses presents a potential therapeutic target.

Purpose of the Study:

  • To develop and characterize novel inhibitory peptides targeting the SARS-CoV-2 Envelope (E) protein.
  • To evaluate the therapeutic potential of these peptides against SARS-CoV-2 infection.
  • To explore the adaptability of these peptides for other human coronaviruses.

Main Methods:

  • Development of screening platforms based on E protein-induced alterations in proton homeostasis and NFAT/AP-1 pathways.
  • Design and optimization of inhibitory peptides (iPep-SARS2-E) against SARS-CoV-2 E protein.
  • In vitro and in vivo testing using cell cultures (Vero-E6), lung organoids, and mouse models.

Main Results:

  • iPep-SARS2-E significantly inhibits SARS-CoV-2 virus egress.
  • The peptide reduces viral cytotoxicity and propagation in both in vitro and in vivo models.
  • The developed peptide strategy is customizable for other human coronaviruses, including MERS-CoV.

Conclusions:

  • The SARS-CoV-2 Envelope (E) protein is a viable therapeutic target for developing antiviral strategies.
  • iPep-SARS2-E demonstrates significant potential for inhibiting SARS-CoV-2 and related coronaviruses.
  • Targeting the conserved E protein offers a promising avenue for broad-spectrum coronavirus therapeutics.